39.07
price down icon1.98%   -0.79
after-market Dopo l'orario di chiusura: 39.07
loading
Precedente Chiudi:
$39.86
Aprire:
$39.04
Volume 24 ore:
685.09K
Relative Volume:
1.71
Capitalizzazione di mercato:
$2.52B
Reddito:
-
Utile/perdita netta:
$-80.77M
Rapporto P/E:
-30.76
EPS:
-1.27
Flusso di cassa netto:
$-80.80M
1 W Prestazione:
-3.71%
1M Prestazione:
-6.44%
6M Prestazione:
-22.51%
1 anno Prestazione:
-22.22%
Intervallo 1D:
Value
$37.26
$40.69
Intervallo di 1 settimana:
Value
$37.26
$41.35
Portata 52W:
Value
$36.52
$58.26

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Name
Nome
Moonlake Immunotherapeutics
Name
Telefono
41 41 510 8022
Name
Indirizzo
DORFSTRASSE 29, ZUG
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
MLTX's Discussions on Twitter

Confronta MLTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
MLTX
Moonlake Immunotherapeutics
39.07 2.52B 0 -80.77M -80.80M -1.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-18 Iniziato RBC Capital Mkts Outperform
2025-01-17 Aggiornamento Goldman Neutral → Buy
2024-11-05 Ripresa Wedbush Outperform
2024-08-26 Downgrade Wolfe Research Outperform → Peer Perform
2024-06-25 Iniziato Oppenheimer Outperform
2024-04-02 Iniziato Goldman Neutral
2024-02-15 Iniziato Wolfe Research Outperform
2023-12-08 Iniziato Citigroup Buy
2023-11-02 Iniziato Stifel Buy
2023-09-14 Downgrade Bryan Garnier Buy → Neutral
2023-08-31 Iniziato Needham Buy
2023-06-15 Iniziato Barclays Equal Weight
2023-05-01 Iniziato Guggenheim Buy
2023-03-22 Iniziato Wedbush Outperform
2023-03-09 Iniziato BTIG Research Buy
2023-02-14 Iniziato Cantor Fitzgerald Overweight
2023-02-02 Iniziato Bryan Garnier Buy
2022-11-11 Iniziato Jefferies Buy
2022-08-25 Iniziato SVB Leerink Outperform
2022-07-21 Iniziato H.C. Wainwright Buy
2022-07-07 Iniziato Cowen Outperform
Mostra tutto

Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie

pulisher
07:22 AM

MoonLake’s 37% decline validates InvestingPro’s overvaluation warning By Investing.com - Investing.com India

07:22 AM
pulisher
Mar 22, 2025

Long Term Trading Analysis for (MLTX) - Stock Traders Daily

Mar 22, 2025
pulisher
Mar 20, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Bought by PNC Financial Services Group Inc. - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

BTIG maintains Moonlake stock Buy rating and $81 target By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 19, 2025

MoonLake Immunotherapeutics’ Sonelokimab Positioned as Leading Treatment for Hidradenitis Suppurativa Amidst Weak JAK Inhibitor Competition - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

BTIG maintains Moonlake stock Buy rating and $81 target - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Coverage Initiated by Analysts at Royal Bank of Canada - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

MoonLake earns new Outperform at RBC Capital Markets on lead drug - MSN

Mar 18, 2025
pulisher
Mar 18, 2025

RBC Capital Initiates Coverage of MoonLake Immunotherapeutics (MLTX) with Outperform Recommendation - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

MoonLake stock earns new Outperform at RBC (MLTX:NASDAQ) - Seeking Alpha

Mar 18, 2025
pulisher
Mar 18, 2025

Why MoonLake Immunotherapeutics Shares Are Rising - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? - MSN

Mar 18, 2025
pulisher
Mar 18, 2025

Guggenheim maintains $80 target on Moonlake Immunotherapeutics stock - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

MoonLake Immunotherapeutics initiated with an Outperform at RBC Capital - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Correction: RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $67 Price Target - MarketScreener

Mar 18, 2025
pulisher
Mar 18, 2025

RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $17 Price Target - Marketscreener.com

Mar 18, 2025
pulisher
Mar 17, 2025

MoonLake Immunotherapeutics: Advancing Sonelokimab with Promising Phase III VELA Program and Favorable Market Positioning - TipRanks

Mar 17, 2025
pulisher
Mar 15, 2025

MoonLake Immunotherapeutics Advances Clinical Trials in 2024 - TipRanks

Mar 15, 2025
pulisher
Mar 14, 2025

MoonLake’s CEO on its looming mid-year pivotal readout in skin disease - Endpoints News

Mar 14, 2025
pulisher
Mar 14, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by Victory Capital Management Inc. - Defense World

Mar 14, 2025
pulisher
Mar 12, 2025

Cowen maintains Buy on Moonlake Immunotherapeutics stock By Investing.com - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

Cowen maintains Buy on Moonlake Immunotherapeutics stock - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

MoonLake Immunotherapeutics: Promising Prospects for Sonelokimab in Inflammatory Diseases - TipRanks

Mar 12, 2025
pulisher
Mar 08, 2025

Why MoonLake Immunotherapeutics is the Dark Horse Pharma Stock to Watch in 2025 - DSA

Mar 08, 2025
pulisher
Mar 05, 2025

Optimistic Outlook for MoonLake Immunotherapeutics: Promising Developments and Market Opportunities for Sonelokimab - TipRanks

Mar 05, 2025
pulisher
Mar 03, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

The Goldman Sachs Group Cuts MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $73.00 - Defense World

Mar 02, 2025
pulisher
Mar 01, 2025

Brokers Offer Predictions for MLTX Q2 Earnings - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

MoonLake Immunotherapeutics (MLTX) Projected to Post Earnings on Thursday - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

(MLTX) Technical Pivots with Risk Controls - Stock Traders Daily

Feb 28, 2025
pulisher
Feb 28, 2025

The Goldman Sachs Group Has Lowered Expectations for MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

MoonLake Immunotherapeutics' (MLTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Needham & Company LLC Increases MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $66.00 - MarketBeat

Feb 28, 2025
pulisher
Feb 27, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Issues Earnings Results, Misses Expectations By $0.09 EPS - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

MoonLake Immunotherapeutics: Buy Rating Backed by Promising SLK Data and Strong Financial Position - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

MoonLake Immunotherapeutics (MLTX) to Release Quarterly Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 27, 2025

Buy Rating for MoonLake Immunotherapeutics Driven by Promising Clinical Programs and Market Potential - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Moonlake Immunotherapeutics Faces Hurdles in Commercializing SLK Despite Potential Approvals - TipRanks

Feb 27, 2025
pulisher
Feb 26, 2025

MoonLake Immunotherapeutics: Strong Buy Rating Amid Promising Phase 3 Trials and Robust Financial Position - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Buy Rating for MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

MoonLake Immunotherapeutics: Promising Future with Strong Financial Position and Clinical Advancements - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

MoonLake Immunotherapeutics reports Q4 EPS (72c), consensus (59c) - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

MoonLake Immunotherapeutics Q4 Loss Widens -February 26, 2025 at 07:53 am EST - Marketscreener.com

Feb 26, 2025
pulisher
Feb 26, 2025

Earnings Flash (MLTX) MoonLake Immunotherapeutics Posts Q4 Loss of $-0.72 a Share, vs. FactSet Est of $-0.59 Loss - Marketscreener.com

Feb 26, 2025
pulisher
Feb 26, 2025

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - The Manila Times

Feb 26, 2025
pulisher
Feb 26, 2025

MoonLake Immunotherapeutics SEC 10-K Report - TradingView

Feb 26, 2025
pulisher
Feb 25, 2025

Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now? - Insider Monkey

Feb 25, 2025
pulisher
Feb 24, 2025

This MoonLake Immunotherapeutics Insider Reduced Their Stake By 50% - simplywall.st

Feb 24, 2025
pulisher
Feb 23, 2025

MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts - Insider Monkey

Feb 23, 2025

Moonlake Immunotherapeutics Azioni (MLTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Capitalizzazione:     |  Volume (24 ore):